Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moyle

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2009
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsMartin Fisher, Graeme J Moyle, Mohsen Shahmanesh, et al.
HIV Medicine|November 5, 2005
Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backboneR Jones, S Sawleshwarkar, C Michailidis, et al.
AIDS (London, England)|September 15, 2004
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenMarta Boffito, Michael Kurowski, Guido Kruse, et al.
Antiviral Therapy|August 1, 2013
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT studyGraeme J Moyle, Hans-Jürgen Stellbrink, Juliet Compston, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 26, 2002
Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmissionVicharn Vithayasai, Graeme J Moyle, Volaluck Supajatura, et al.
The British Journal of Nutrition|June 2, 2009
Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected menLisa J Ware, Akil G A Jackson, Stephen A Wootton, et al.
AIDS (London, England)|October 21, 2006
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophyGraeme J Moyle, Caroline A Sabin, Jonathan Cartledge, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2005
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimensSimon P Jones, Nadeem Qazi, John Morelese, et al.
Antiviral Therapy|March 6, 2012
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityGraeme J Moyle, Jaime Andrade-Villanueva, Pierre-Marie Girard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2009
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsMartin Fisher, Graeme J Moyle, Mohsen Shahmanesh, et al.
HIV Medicine|November 5, 2005
Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backboneR Jones, S Sawleshwarkar, C Michailidis, et al.
AIDS (London, England)|September 15, 2004
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenMarta Boffito, Michael Kurowski, Guido Kruse, et al.
Antiviral Therapy|August 1, 2013
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT studyGraeme J Moyle, Hans-Jürgen Stellbrink, Juliet Compston, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 26, 2002
Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmissionVicharn Vithayasai, Graeme J Moyle, Volaluck Supajatura, et al.
The British Journal of Nutrition|June 2, 2009
Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected menLisa J Ware, Akil G A Jackson, Stephen A Wootton, et al.
AIDS (London, England)|October 21, 2006
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophyGraeme J Moyle, Caroline A Sabin, Jonathan Cartledge, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2005
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimensSimon P Jones, Nadeem Qazi, John Morelese, et al.
Antiviral Therapy|March 6, 2012
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityGraeme J Moyle, Jaime Andrade-Villanueva, Pierre-Marie Girard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Pageof 8